Kornimate/medical-research-clean huggingface dataset:
effectiveness of the self monitoring of capillary blood glucose at home

Conditions: Diabetes Mellitus

Summary: the self-monitoring of capillary blood glucose is part of the package of interventions in diabetes mellitus and an effective therapeutic strategy for the adequate control of the disease; and the continuing education of people with dm is recognized as one of the goals to delay the complications arising from chronic disease and alleviate the symptoms of hypoglycemia and hyperglycemia.

this study aims to evaluate the effects of educational intervention on self-monitoring of capillary blood glucose in metabolic control, knowledge and attitude in two groups of patients with diabetes mellitus: a group of diabetic patients who participate in the self-monitoring of capillary blood glucose at home program and receive educational interventions (intervention group - g1) and a group of diabetic patients who participle in the self-monitoring of capillary blood glucose at home program and receive conventional treatment (control group - g2). as an educational tool in diabetes will be used conversation maps which is considered an interactive program of diabetes education.

Eligibility criteria:
inclusion criteria: * ages 18 years and older; * diagnosis of type 1 and 2 diabetes mellitus; * in follow-up in the self-monitoring of capillary blood glucose at home program; * have cognitive conditions that enable participation (minimum ability of users to understand issues of data collection instruments, observation of the researcher and/or of the caregivers). exclusion criteria: * patients with gestational dm; * patients with dm who are not located; * those who die in the proposed period for the research; * those who dropout the self-monitoring of capillary blood glucose at home program; * those who report difficulties to participate of the study due to work and those with amaurosis; * used conversation maps as an educational tool.
evaluate the usefulness of mental health e-learning

Conditions: Depression; Anxiety

Summary: in this proposal, the investigators plan to study the impact of in this proposal, we plan to study the impact of e-learning on mental health literacy and stigma related to anxiety and depression. participants will be randomized to one of four groups - depression e-learning a, depression e-learning b, anxiety e-learning a, and anxiety e-learning b. all participants will be given access to all e-learning at the conclusion of the study.


Eligibility criteria:
inclusion criteria: * live in canada * 45 years of age and over * good command of the english language * access to email and high speed internet * comfortable using email and internet exclusion criteria: * lives outside of canada * not 45 years of age or over * does not speak english, * does not have access to email or high speed internet * is not comfortable using email of internet

Keywords: depression mental health mental health literacy e-learning knowledge stigma randomized controlled trial
multiple-dose pharmacokinetics of doripenem during continuous venovenous hemodiafiltration and molecular adsorbent recirculating system in icu patients and during hemodialysis in longterm hemodialysis patients.

Conditions: Infections During Organ Replacement Therapy

Summary: the study is conducted to investigate the pharmacokinetics of doripenem during cvvhdf (continuous venovenous hemodiafiltration), mars (molecular adsorbent recirculating system) and intermittent hemodialysis.


Eligibility criteria:
inclusion criteria: * age \>18 years * suspected or proven bacterial infection requiring parenteral antibiotic therapy. * organ replacement therapy (mars, cvvhdf or hd) exclusion criteria: * known hypersensitivity to doripenem or other carbapenems, or severe hypersensitivity (anaphylactic reaction) to beta-lactam antibacterial agents. * an expected survival of less than two days. * known pregnancy * coadministration of valproic acid or probenecid, which cannot be discontinued for the duration of the study * doripenem as monotherapy for resistent species or fungal infections. * other reasons opposing the study participation on the discretion of the investigators.

Keywords: pharmacokinetics, doripenem, renal replacement therapy, mars, organ replacement therapy
phase ii cancer vaccine trial for patients with follicular lymphoma

Conditions: Follicular Lymphoma

Summary: patients with non-curable disseminated follicular lymphoma receive local radiotherapy targeting single lymph nodes and injection of low-dose rituximab (anti-cd20) and autologous dendritic cells. the therapy is repeated 3 times, targeting different lesion. aims are to induce tumor immunity and clinical responses.

the clinical protocol is based on the rationale that the immune system has been developed to combat infectious disease. to mimic the environment in infected tissue, selected tumor-affected lymph nodes are treated locally with a single dose of 8 gy radiotherapy and injected with therapeutic antibody (anti-cd20/rituximab). later, dendritic cells (dc) are injected into the damaged tumor tissue together with a stimulatory cytokine (gm-csf) to initiate an immune response. patients with untreated or relapsed stage iii/iv follicular lymphoma not in need of standard therapy receive intra-tumoral injections of low-dose anti-cd20 antibodies (5 mg) on days 1 and 3 and local radiotherapy on day 2. on days 4 and 5, dendritic cells generated from monocytes isolated from the patients blood are injected into the site together with the stimulatory cytokine gm-csf administered subcutaneously. additional lymph nodes are treated similarly after 2 and 4 weeks. the treatment is thus performed three times, targeting different lymphoma nodes. the primary aims are to induce tumor-specific immune responses and clinical responses.

Eligibility criteria:
inclusion criteria: 1. age 18 years and older 2. histologically confirmed (by who classification) untreated and relapsed indolent non-hodgkin's b-cell lymphoma of low-grade follicular, marginal zone, lymphoplasmocytic or small lymphocytic subtypes. 3. stage iii/iv 4. adequate bone marrow function (leukocyte count\>2,0, neutrophil count\>1.0, platelets\>50) 5. two or more separate lymph nodes \> 1,5 cm available for biopsy or treatment. 6. measurable disease present other than biopsy site and injection site(s). 7. required wash-out period after previous treatment: chemotherapy - 8 weeks, radiotherapy - 4 weeks, rituximab - 12 weeks 8. who status 0-1 9. life expectancy of more than 6 months 10. written informed consent 11. able to comply with the treatment protocol - exclusion criteria: 1. patients with progressive lymphoma in need of systemic therapy or standard dose irradiation. 2. chronic bacterial, viral or fungal infection 3. pre-existing autoimmune or antibody mediated disease including: systemic lupus, erythematosus, rheumatoid arthritis, multiple sclerosis, sjogren's syndrome, autoimmune thrombocytopenia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease. 4. known history of hiv 5. central nervous system involvement of lymphoma 6. current anticoagulant therapy which can not safely be paused during treatment injections (asa \< 325 mg/day allowed) 7. pregnancy -

Keywords: follicular lymphoma rituximab autologous dendritic cells cancer vaccine
effects of multidisciplinary interventions in elderly asthma patients with risk of acute exacerbation

Conditions: Asthma; Aged

Summary: we want to examine the effect of multidisciplinary interventions in asthma patients who had experienced acute exacerbation of asthma. in our previous observational studies, elderly asthma patients had a some distinct features such as impairment of cognitive function, deficiency of micronutrient and absence of caregiver compared with young adult asthmatics. we wanted to evaluate whether the long-term course of asthma could be modified by intervening deficienies which were found in elderly patiensts. so, we designed a interventional study to correct above risk factors in elderly asthma patients, which could be aggravating their asthma. followings are our specific multidiciplinary items that we want to correct. 1. popularize and educate the asthma action plan 2. run a emergency call system for acute exacerbation 3. educate the proper techniques using inhalers 4. correct the deficiency of magnesium (magnesium 500 mg per day) after 1 years, we will measure the numbers of acute exacerbations, lung function including fev1 and fev1/fvc, health-related quality of life and level of serum magnesium in study patients.


Eligibility criteria:
inclusion criteria: * elderly asthma patients who had experienced acute exacerbation of asthma 1)aggravations of any of major criteria * dyspnea * cough * wheezing * increase or purulent changes of sputum * nocturnal symptoms 2)aggravation of more than one of following criteria * a reduction of forced expiratory volume at one second or peak expiratory flow rate more than 20% compared than one's best score * unscheduled clinic or emergency department visit or admission * step-up of dose of asthma medications or any intake of systemic steroids

Keywords: acute exacerbation quality of life magnesium deficiency multidisciplinary intervention
predictive impact of mmp2 and mmp9 levels for patients with metastatic kidney cancer treated with anti-angiogenic agents

Conditions: Kidney Cancer

Summary: prospective research of matrix metalloproteinases (mmp) 2 and 9 as predictive biomarkers in metastatic kidney cancer patients treated with 2 anti angiogenic agents (sunitinib or pazopanib).

the objective is to analyze the predictive impact of circulating mmp2 and mmp9 on the progression-free survival of patients with metastatic kidney cancer treated with anti-angiogenic agents (sunitinib or pazopanib) in comparison with two untreated cohorts (localized or oligometastatic cancer). prospective monocenter, open-label study in the frame of disease management blood samples will be collected at different times of follow-up regarding disease status (localized, oligometastatic and metastatic) and tissue samples will be collected for patients scheduled for surgery.

Eligibility criteria:
inclusion criteria: 1. patient male or female, aged of more than 18 years 2. patient with any of the following conditions: * kidney cancer localized at diagnosis. * metastatic kidney cancer when anti-angiogenic therapy is initiated by sunitinib or pazopanib * oligometastatic kidney cancer without systemic treatment (local treatment) 3. ecog = 0 to 2 4. patient affiliated to, or beneficiary of, the national social security. 5. patient having signed informed consent exclusion criteria: 1. patient previously treated with anti-angiogenic agents. 2. person in an emergency situation, adult subject to a legal protection measure (a guardian, guardianship or safeguard of justice), or unable of expressing his / her consent. 3. impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons 4. history of malignant disease in the 5 years prior to inclusion (except basal cell carcinoma of the skin or epithelioma of the cervix in situ, or prostate cancer with a good prognosis (stage t \<3 and gleason \<7)) accidentally discovered during the histological analysis of the tumor sample. 5- pregnant or nursing women 6- contraindications to the procedure of the study
recover-neuro: platform protocol, appendix_a to measure the effects of brainhq, pasc core and tdcs interventions on long covid symptoms

Conditions: Long COVID; Long Covid19; Long Covid-19

Summary: this platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into covid-19 programs and subsequent treatment plans. this protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating potential interventions for pasc-mediated cognitive dysfunction. the hypothesis is that pasc-associated dysfunction in cognitive domains, such as executive function and attention, may be improved by interventions that selectively focus on enhancing those domains. this design seeks to evaluate each intervention relative to the active comparator. the brainhq (alone) arm is important because the intervention is commercially available, accessible, relatively inexpensive, and does not require trained personnel to administer. brainhq has been also been proven effective in other studies of cognitive dysfunction such as studies in aging, mild cognitive impairment, traumatic brain injury, among others. the brainhq + pasc core arm and the brainhq + tdcs arms are suspected to provide cognitive improvements beyond brainhq alone through different mechanisms. both pasc core and tdcs have extensive prior use and have demonstrated utility in improving aspects of cognitive function in other clinical settings..

participants will be randomized to one of the intervention appendices that are actively enrolling at the time of randomization. intervention appendices may be added or removed according to adaptive design and/or emerging evidence. various interventions will be studied. participants will be randomized equally across the five arms: 1. active comparator (video games) 2. brainhq 3. brainhq + pasc core 4. brainhq + tdcs-active 5. brainhq + tdcs-sham

Eligibility criteria:
inclusion criteria: 1. see nct05965752 for recover-neuro: platform protocol level inclusion criteria which applies to this appendix exclusion criteria: 1. see nct05965752 for recover-neuro: platform protocol level exclusion criteria which applies to this appendix additional appendix (sub-study) level exclusion criteria: 1. presence of metal objects in the head or neck 2. skin disorders or skin-sensitive areas near tdcs stimulation locations that would interfere with electrode placement or increase the risk of stimulation-induced damage, at the investigator's discretion

Keywords: pasc cognitive
clopidogrel/aspirin interaction study

Conditions: Coronary Artery Disease

Summary: this study will explore the effect of different doses of aspirin on the effects of double-dose or standard dose clopidogrel.

study hypothesis: patients receiving double-dose compared with standard-dose clopidogrel will have increased blood concentrations of the active metabolite of clopidogrel and greater inhibition of adp-induced platelet aggregation when also treated with acetylsalicylic acid (asa) 325 mg/d as compared to asa 81 mg/d.

Eligibility criteria:
inclusion criteria: * \> 1 month post myocardial infarction (mi), unstable angina or stent patients with stable condition * receiving regular asa (81mg/d) and clopidogrel (75mg/d) for at least 1 week * written informed consent exclusion criteria: * age \< 18 years old * liver disease with transaminases and/or bilirubin \> 1.5x upper limits of normal (uln) (within 3 months of randomization) * renal impairment with creatinine clearance \< 30 ml/min (within 3 months of randomization) * platelet count \< 100x109/l and/or hb\< 100g/l (within 3 months of randomization) * use of oral anticoagulants or nonsteroidal antiinflammatory drug (nsaid) within the last 10 days or planned use during the study * use of antiplatelet agent other than aspirin and clopidogrel within the last 10 days * high risk of bleeding (e.g. recent gastrointestinal bleeding, bleeding diathesis) * uncontrolled hypertension (\> 180/110mmhg) * current smoker with ≥ 5 cigarettes/day * previously entered in this study or just finished other study within 2 weeks before recruitment * medical, geographic, or social factors making study participation impractical, or inability to provide written informed consent

Keywords: clopidogrel aspirin interaction
safety and efficacy of r-cmop versus r-chop in the initial treatment of dlbcl

Conditions: Diffuse Large B-Cell Lymphoma

Summary: this is a prospective, randomized, controlled, multicenter, phase ii clinical trial to evaluate the efficacy and safety of r-cmop versus r-chop in the initial treatment of low-risk and medium-risk diffuse large b-cell lymphoma (dlbcl).


Eligibility criteria:
key inclusion criteria: 1. aged ≥18,≤80 years, both male and female. 2. pathologically confirmed dlbcl 3. no prior treatment for dlbcl. 4. there must be at least one measurable or evaluable lesion that meets the evaluation criteria for lugano 2014 lymphoma. 5. eastern cooperative oncology group (ecog) performance status score of 0- 6. expected survival ≥3 months. 7. international prognostic index (ipi) ≤ 2 8. sufficient bone marrow, liver, and kidney function. key exclusion criteria: 1. other types of lbcl:primary cutaneous diffuse large b-cell lymphoma (leg type), primary mediastinal (thymic) large b-cell lymphoma, lymphomatoid granulomatosis, alk-positive diffuse large b-cell lymphoma, plasmablastic lymphoma, intravascular large b-cell lymphoma, t-cell/histiocyte-rich large b-cell lymphoma, and others. 2. transformed dlbcl. 3. patients with central nervous system involvement, or those who require high-dose methotrexate for prevention. 4. the patients had previously received antitumor therapy. 5. patients with the infection of human immunodeficiency virus (hiv) and/or acquired immunodeficiency syndrome. 6. pregnant and lactating women and subjects of childbearing age who do not want to use contraception. 7. mentally ill persons or persons unable to obtain informed consent. 8. the investigators think that the patient is not suitable for the study.

Keywords: dlbcl r-chop liposomal mitoxantrone
brief intervention for prescription drug misuse in general hospital

Conditions: Substance-related Disorders

Summary: in a randomized controlled trial, patients recruited in a general hospital and fulfilling criteria for regular consumption (more than 60 days within the last three months), dependence or abuse of prescription drugs will be randomly allocated to two conditions:(1) intervention group consisting of two counselling sessions based on motivational interviewing plus a personalized feedback, (2) control group receiving a booklet on health behavior. outcome assessment will be conducted after 12 months. the hypothesis is that counseling leads to greater reduction in consumption of prescription drugs (including discontinuation) and elevated readiness to change at follow-up.

background: dependence on prescription drugs (dpd) is highly prevalent, whereby rate of substance specific treatment is low. a pilot study revealed elevated prevalence rates in general hospital patients compared to the general population and a positive attitude of patients suffering from dpd towards counseling. brief intervention delivered in general hospital might be useful to promote discontinuation of prescription drug use and utilization of formal help. objectives: to test the efficacy of a brief intervention based on motivational interviewing in proactively recruited general hospital patients randomly allocated to an intervention or a control group. methods: patients aged 18 to 69 years are proactively recruited in surgical and internal wards of two general hospitals in the northern german city of lübeck. patients with regular use of prescription drugs in the last three months and/or prescription drug dependence or -abuse are randomly assigned to two conditions: (1) an intervention group with two counseling sessions based on motivational interviewing plus one individualized feedback based on the transtheoretical model of behavior change (ttm) or (2) as usual care. outcome measures are reduction or discontinuation of prescription drug use and utilization of formal help. the efficacy of the intervention will be examined within a 3 and a 12 month follow up. expected impact: findings are expected to provide evidence for brief interventions for prescription drug misuse to be used in primary care. this would be the first international results confirming such an approach in the field of prescription drug misuse. if a brief interventions would be effective, this could enhance secondary prevention for this under served population. therefore, data are of great public health interest.

Eligibility criteria:
inclusion criteria: * prescription drug abuse * prescription drug dependence * regular prescription drug consumption (\>60 times/last three months) exclusion criteria: * current treatment for substance abuse problems * terminal illness

Keywords: prescription drug use disorder brief intervention general hospital motivational interviewing
segmentectomy vs lobectomy

Conditions: Non-small Cell Lung Cancer Stage I; Surgery

Summary: actual indications for stage ia nsclc patients suggest lobectomy and lymphadenectomy. on the other hand, recent studies reported non-inferiority of segmentectomy in case of nodule \< 2cm or with ground glass appearance at computed tomography. however, most of these studies did not report specifical analysis on kind of segmentectomy (single or multiple) and kind of lobectomy. moreover, a specific study on solid nodules only is still missing. for these reasons, the effectiveness of segmentectomy instead lobectomy for every kind of segment or tumor is still to be defined. aim of this study is to analyze survival outcome in patients underwent single or multiple segmentectomy compared to lobectomy in stage i non small cell lung cancer.


Eligibility criteria:
inclusion criteria: * adenocarcinoma or squamous cell carcinoma * cstage cia with or without nodal upstaging * lymphoadenectomy * age \> 18 years old * radical resection * anatomical resection (lobectomy or segmentectomy) * pet ct done exclusion criteria: * nodal or distant metastasis confirmed before surgery * pure solid ggo * follow up \< 12 months * bilobectomy/pneumonectomy * trans fissure tumor * multiple lung tumors

Keywords: segmentectomy lobectomy
methodology antiseptic application, influence on oral biofilm.

Conditions: Oral Biofilm; Periodontitis; Gingivitis

Summary: the study has the objective to compare two different methodology of application the antiseptic on the oral biofilm will be formed during 48h in situ on a specific device. the first one using the immersion in the antiseptic solution, as much of the authors did in the past. and the second way doing a active mouthwash, as the manufacturer recommends. the study will compare two different antiseptic solutions, the chlorhexidine (0.2% oraldine perio) and the essential oils (listerine mentol) with the two different application and compared the bacterial vitality, thickness and covering grade between solutions and with a basal sample.

15 healthy volunteers, between 20 and 45 years old, will use during 48 hours two specific oral devices with 3 glass disks each. after this period, one of the disk will be drawn from the device and it will be immersed in live/dead baclight solution for 15 minutes and then the disk will be analysed by the confocal laser scanning microscope (clsm). immediately, another disk will be removed from the intraoral device and immersed in the antiseptic solution, being analysed by the clsm as well. after that, the volunteers will do the mouthwash with the antiseptic solution (as stated in the specific protocol) and the last disk will be drawn from the device and will be analysed by the clsm following the same protocol. the other 3 disk will undergo the same protocol of baseline, immersion and mouthwash, but with the other antiseptic solution. the clsm data will be analysed and the bacterial vitality, thickness and covering grade will be calculated. finally the statistical analysis will be applied (pairwise comparisons, with the bonferroni adjustment).

Eligibility criteria:
inclusion criteria: * good oral health status: a minimum of 24 permanent teeth with no evidence of gingivitis or periodontitis and absence of untreated caries exclusion criteria: * smoker or former smoker * presence of dental prostheses or orthodontic devices * antibiotic treatment or routine use of oral antiseptics in the previous three months * presence of any systemic disease that could alter the production or composition of saliva

Keywords: essential oils chlorhexidine microscopy, confocal immersion antiseptic